We are live on ! Find out more
EFTR

eFFECTOR Therapeutics, Inc. Common Stock
EFTR

Delisted

EFTR was delisted on the 2nd of July, 2024.

Back to rankings

33 hedge funds and large institutions have $20.2M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,771% more call options, than puts

Call options by funds: $393K | Put options by funds: $21K

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

103% more capital invested

Capital invested by funds: $9.94M → $20.2M (+$10.2M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

27% more funds holding

Funds holding: 26 → 33 (+7)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
33
Holders Change
+7
Holders Change %
+26.92%
% of All Funds
0.52%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
10
Increased
2
Reduced
3
Closed
3
Calls
$393K
Puts
$21K
Net Calls
+$372K
Net Calls Change
+$337K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$498K
2
Two Sigma Investments
Two Sigma Investments
New York
+$55.1K
3
HF
HRT Financial
New York
+$21K
4
XT
XTX Topco
Cayman Islands
+$19.5K
5
Morgan Stanley
Morgan Stanley
New York
+$12.2K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$35.5K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$10.5K
3
TSS
Two Sigma Securities
New York
-$8.69K
4
UBS Group
UBS Group
Switzerland
-$7.56K
5
GSC
Ground Swell Capital
South Carolina
-$4.23K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$5.59M – – –
CG
2
Carlyle Group
District of Columbia
$3.95M – – –
CG
3
Column Group
California
$3.58M – – –
SAM
4
Sectoral Asset Management
Quebec, Canada
$1.98M – – –
PA
5
Parallel Advisors
California
$1.41M – – –
Blackstone Inc
6
Blackstone Inc
New York
$1.09M – – –
OMC
7
OUP Management Company
Pennsylvania
$852K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$731K +$498K +29,480 +512%
Vanguard Group
9
Vanguard Group
Pennsylvania
$337K – – –
SOA
10
Sea Otter Advisors
Florida
$219K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$87.2K – – –
Two Sigma Investments
12
Two Sigma Investments
New York
$67.7K +$55.1K +3,262 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$39.1K -$10.5K -620 -25%
EWA
14
EP Wealth Advisors
California
$25.7K -$1.77K -105 -15%
WFAG
15
Wescott Financial Advisory Group
Pennsylvania
$25.4K – – –
HF
16
HRT Financial
New York
$25K +$21K +1,241 New
XT
17
XTX Topco
Cayman Islands
$23.9K +$19.5K +1,153 New
Northern Trust
18
Northern Trust
Illinois
$21.6K – – –
State Street
19
State Street
Massachusetts
$16.7K – – –
MOS
20
MGO One Seven
Ohio
$16.7K – – –
CC
21
Callan Capital
California
$16.6K – – –
Morgan Stanley
22
Morgan Stanley
New York
$14.9K +$12.2K +720 New
Millennium Management
23
Millennium Management
New York
$11.2K +$9.12K +540 New
Prudential Financial
24
Prudential Financial
New Jersey
$11K +$8.92K +528 New
TRCT
25
Tower Research Capital (TRC)
New York
$8.62K +$34 +2 +0.5%
1
2

EFTR Hedge Fund Activity: Q2 2023 in Review

33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q2 2023, worth a combined $20.2M — up 103% from $9.94M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EFTR positions and 3 closed out — a net gain of 7 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $498K. The largest seller was BlackRock, cutting an estimated $35.5K.

  • 33 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q2 2023, up from 26 in Q1 2023.
  • Funds reported $20.2M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q2 2023, up 103% quarter-over-quarter.
  • 10 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of +7 holders.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q2 2023 was Renaissance Technologies, an estimated $498K added.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q2 2023 was BlackRock, an estimated $35.5K sold.

Based on aggregated 13F filings for Q2 2023.